Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Jonathan Szeto

Internal Medicine Kansas City, MO Medical Doctor

NPI 1780666818 CMS profile 171841

2330 E Meyer Blvd, Suite 101, Kansas City, MO 64132

Open in the dashboard

General payments

$12,920

192 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Jonathan Szeto of Kansas City, MO is reported in the CMS Open Payments database as having received $12,920 across 192 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $28 2
2021 General $2,259 83
2020 General $864 29
2019 General $9,769 78

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jonathan Szeto
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Jonathan Szeto were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Jonathan Szeto Internal Medicine median Middle half National median
2019 $9,769 $159 $48–$570 $163
2020 $864 $119 $33–$402 $114
2021 $2,259 $135 $37–$521 $132
2022 $28 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Otsuka America Pharmaceutical, Inc. $7,646 13 payments
  2. AstraZeneca Pharmaceuticals LP $1,320 23 payments
  3. AbbVie, Inc. $563 26 payments
  4. Novo Nordisk Inc $437 18 payments
  5. Pfizer Inc. $420 33 payments
  6. Janssen Pharmaceuticals, Inc $333 6 payments
  7. Amgen Inc. $264 6 payments
  8. Sanofi-Aventis U.S. LLC $257 6 payments
  9. Foundation Medicine, Inc. $202 1 payment
  10. Novartis Pharmaceuticals Corporation $191 7 payments
  11. Other $1,286 53 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Consulting Fee $6,311 2 payments
  2. Food and Beverage $5,322 181 payments
  3. Travel and Lodging $1,082 7 payments
  4. Compensation for serving as faculty or as a speaker for a medical education program $202 1 payment
  5. Education $3 1 payment
Products named General payments · program years 2019–2022
  1. JYNARQUE $4,740 9 payments
  2. SAMSCA $2,906 4 payments
  3. FARXIGA $746 14 payments
  4. ELIQUIS $346 25 payments
  5. UBRELVY $346 12 payments
  6. XARELTO $333 6 payments
  7. RYBELSUS $243 9 payments
  8. Ozempic $235 12 payments
  9. FOUNDATIONONE CDX $202 1 payment
  10. FOUNDATIONONE $202 1 payment
  11. Other $4,795 214 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

192 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record